Adalimumab (Humira™): A promising monoclonal anti-tumor necrosis factor alpha in ophthalmology

International Ophthalmology

Volumn 31, Issue 2, 2011, Pages 165-173

  Neri, Piergiorgio ^a,b   Zucchi, Manuela ^a   Allegri, Pia ^c   Lettieri, Marta ^a,b   Mariotti, Cesare ^a,b   Giovannini, Alfonso ^a,b  

^a OSPEDALI RIUNITI   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c Hospital of Lavagna   (Italy)

Author keywords

Adalimumab; Immunosuppression; Macular oedema; Uveitis

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; ETANERCEPT; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANKYLOSING SPONDYLITIS; ASEPTIC NECROSIS; BEHAVIOR DISORDER; BEHCET DISEASE; CHILD CARE; CUSHING SYNDROME; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EYE INFLAMMATION; GROWTH DISORDER; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; OPHTHALMOLOGY; OSTEOPOROSIS; OUTCOME ASSESSMENT; PSORIATIC ARTHRITIS; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SECONDARY INFECTION; SYSTEMIC DISEASE; UNSPECIFIED SIDE EFFECT; UVEITIS;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; BEHCET SYNDROME; HUMANS; INTRAVITREAL INJECTIONS; OPHTHALMOLOGY; PEDIATRICS; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 79955985681     PISSN: 01655701     EISSN: 15732630     Source Type: Journal    
DOI: 10.1007/s10792-011-9430-3     Document Type: Review

References (51)

1. Vassalli P (1992) The pathophysiology of tumor necrosis factors. Annu Rev Immunol 10:411-452
2. Chen G, Goeddel DV (2002) TNF-R1 signaling: a beautiful pathway. Science. 296:1634-1635 (Pubitemid 34579145)
3. Saklatvala J (1986) Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature. 322:547-549
4. Selmaj KW, Raine CS (1988) Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 23:339-346 (Pubitemid 18098239)
5. Nussenblatt RB (1991) Proctor Lecture. Experimental autoimmune uveitis: mechanisms of disease and clinical therapeutic indications. Invest Ophthalmol Vis Sci. 32:3131-3141
6. Forrester JV (1992) Duke-Elder lecture: new concepts on the role of autoimmunity in the pathogenesis of uveitis. Eye. 6:433-446
7. Caspi RR, Roberge FG, McAllister CG et al (1986) T cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat. J Immunol 136:928-933 (Pubitemid 16146378)
8. Nakamura S, Yamakawa T, Sugita M et al (1994) The role of tumor necrosis factor-alpha in the induction of experimental autoimmune uveoretinitis in mice. Invest Ophthalmol Vis Sci. 35:3884-3889 (Pubitemid 24334546)
9. Sartani G, Silver PB, Rizzo LV et al (1996) Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming. Invest Ophthalmol Vis Sci. 37:2211-2218 (Pubitemid 26338769)
10. Santos Lacomba M, Marcos Martin C et al (2001) Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 33:251-255 (Pubitemid 34701624)
11. Ahn JK, Yu HG, Chung H, Park YG (2006) Intraocular cytokine environment in active Behçet uveitis. Am J Ophthalmol 142(3):429-434
12. Kramer M, Goldenberg-Cohen N, Axer-Siegel R, Weinberger D, Cohen Y, Monselise Y (2005) Inflammatory reaction in acute retinal artery occlusion: cytokine levels in aqueous humor and serum. Ocul Immunol Inflamm. 13(4):305-310 (Pubitemid 41702774)
13. Pérez-Guijo V, Santos-Lacomba M, Sánchez-Hernández M, Castro-Villegas Mdel C, Gallardo-Galera JM, Collantes-Estévez E (2004) Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27. Curr Med Res Opin 20(2):155-157
14. Xu Y, Chen W, Lu H, Hu X, Li S, Wang J, Zhao L (2010) The expression of cytokines in the aqueous humor and serum during endotoxin-induced uveitis in C3H/HeN mice. Mol Vis. 16:1689-1695 Aug 21
15. Feldmann M, Brennan FM, Maini RN (1996) Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14:397-440 (Pubitemid 26130190)
16. Present DH, Rutgeerts P, Targan S et al (1999) Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340:1398-1405 (Pubitemid 29205403)
17. Weinblatt ME, Kremer JM, Bankhurst AD et al (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253-259 (Pubitemid 29063266)
18. Lim LL, Fraunfelder FW, Rosenbaum JT (2007) Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthr Rheum 56(10):3248-3252 (Pubitemid 47585419)
19. Dick AD, Duncan L, Hale G et al (1998) Neutralizing TNF-αlpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis. J Autoimmun 11:255-264 (Pubitemid 28319791)
20. Yue C, You X, Zhao L et al (2010) The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients. Rheumatol Int 30(12):1553-1557
21. Rudwaleit M, Claudepierre P, Wordsworth P et al (2009) Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 36(4):801-808
22. van den Bosch F, Manger B, Goupille P et al (2010) Effectiveness of adalimumab in treating patients with active psoriatic arthritis (PsA) and predictors of good clinical responses for arthritis, skin, and nail lesions. Ann Rheum Dis 69(2):394-399
23. Imrie F, Dick AD (2007) Biologics in the treatment of uveitis. Curr Opin Ophthalmol 18:481-486 (Pubitemid 351339402)
24. van Vollenhoven RF (2007) Switching between antitumour necrosis factors: trying to get a handle on a complex issue. Ann Rheum Dis 66:849-851
25. Dhingra N, Morgan J, Dick AD (2009) Switching biologic agents for uveitis. Eye (Lond) 23(9):1868-1870
26. Tracey D, Klareskog L, Sasso EH et al (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117(2):244-279
27. Biester S, Deuter C, Michels H et al (2007) Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 91(3):319-324 (Pubitemid 46586527)
28. Wiens A, Correr CJ, Venson R et al (2010) A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis. Rheumatol Int 30(8):1063-1070
29. Schmitt J, Wozel G (2009) Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature. Biologics 3:303-318
30. van de Putte LBA, Atkins C, Malaise M et al (2004) Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 63:508-516 (Pubitemid 38530193)
31. den Broeder A, van de Putte LBA, Rau R et al (2002) A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-α antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol 29: 2288-2298 (Pubitemid 35266018)
32. Keystone EC, Kavanaugh AF, Sharp JT et al (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. Arthr Rheum 5:1400-1411 (Pubitemid 38608061)
33. Weinblatt ME, Keystone EC, Furst DE et al (2003) Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. Arthr Rheum 1:35-45 (Pubitemid 36091645)
34. Weinblatt ME, Keystone EC, Furst DE et al (2006) Long-term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4-year extended study. Ann Rheum Dis 65:753-759 (Pubitemid 43799174)
35. Olivieri I, Scarano E, Gigliotti P et al (2006) Successful treatment of juvenile-onset HLA-B27-associated severe and refractory heel thesitis with adalimumab documented by magnetic resonance imaging. Rheumatology 45(10):1315-1317 (Pubitemid 44542082)
36. Adams AB, Kazim M, Lehman TJA (2005) Treatment of orbital myositis with adalimumab (Humira). J Rheumatol 32:1374-1375 (Pubitemid 40995400)
37. de Vos AF, van Haren MAC, Verhagen C et al (1994) Kinetics of intraocular tumor necrosis factor and interleukin-6 in endotoxin-induced uveitis in the rat. Invest Ophthalmol Vis Sci 35:1100-1106 (Pubitemid 24079844)
38. de Vos AF, van Haren MAC, Verhagen C et al (1995) TNF-induced uveitis in the Lewis rat is associated with intraocular interleukin 6 production. Exp Eye Res 60:199-207
39. Rosenbaum JT, Howes EL, Rubin RM et al (1988) Ocular inflammatory effects of intravitreally-injected tumor necrosis factor. Am J Pathol 133:47-53
40. Ebell MH, Siwek J, Weiss BD, Woolf SH, Susman J, Ewigman B, Bowman M (2004) Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. J Am Board Fam Pract 17(1):59-67
41. Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 140:509-516 (Pubitemid 41224845)
42. Avunduk MC, Avunduk AM, Oztekin E et al (2004) Etanercept treatment in the endotoxin-induced uveitis of rats. Exp Eye Res 79:357-365 (Pubitemid 39164473)
43. Koizumi K, Poulaki V, Doehmen S et al (2003) Contribution of TNF-α to leukocyte adhesion, vascular leakage, and apoptotic cell death in endotoxin-induced uveitis in vivo. Invest Ophthalmol Vis Sci 44:2184-2191 (Pubitemid 36520316)
44. Rudwaleit M, Rødevand E, Holck P et al (2009) Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 68(5):696-701
45. Mushtaq B, Saeed T, Situnayake RD et al (2007) Adalimumab for sight-threatening uveitis in Behçet's disease. Eye (Lond) 21(6):824-825 (Pubitemid 46909189)
46. Takase K, Ohno S, Ideguchi H et al (2011) Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitis. Rheumatol Int 31(2):243-245
47. Diaz-Llopis M, García-Delpech S, Salom D et al (2008) Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther 24(3):351-361 (Pubitemid 351733224)
48. Doycheva D, Deuter C, Stuebiger N et al (2007) Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol 91(2):180-184 (Pubitemid 46202865)
49. Tynjälä P, Kotaniemi K, Lindahl P et al (2008) Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford) 47(3):339-344 (Pubitemid 351267203)
50. Androudi S, Tsironi E, Kalageropoulos C et al. (2010) Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmol 117(8):1612-1616
51. Robertson M, Liversidge J, Forrester J et al (2003) Neutralising TNF-alpha activity suppresses activation of infiltrating macrophages in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 44:3034-3041 (Pubitemid 36759770)